Business

Business

At Illumina, the faster we can innovate, the more lives we can help save.  As a genomics pioneer, we have proven through focused and continued innovation how unlocking the power of the genome can exponentially improve the human condition. Our ability to drive patient outcomes has made us a trusted partner in healthcare. Today, we’re providing tools that enable the next generation of researchers and clinicians to usher in the future of personalized medicine. Innovating at the intersection of technology, biology, and health, we are re-imagining what’s possible for clinicians, transforming how they detect, diagnose, and treat cancer, and rare, infectious, and genetic diseases.

Content from this campaign

Illumina To Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022
SAN DIEGO, October 24, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022. Francis deSouza, President and Chief Executive Officer, Aimee Hoyt, Chief People Officer, John Frank, Chief...
Oct 24, 2022 9:00 AM ET
Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum
New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability
Oct 3, 2022 2:15 PM ET
Illumina Unveils Revolutionary NovaSeq X Series To Rapidly Accelerate Genomic Discoveries and Improve Human Health
New technology enables highest levels of accuracy at immense scale, with the power to sequence more than 20,000 genomes per year Our most sustainable high-throughput sequencer delivers 90% reduction in packaging and 50% reduction in plastic waste, and eliminates dry ice shipments, expanding global access to genomic...
Sep 30, 2022 9:30 AM ET
Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients
SAN DIEGO, September 7, 2022 / 3BL Media / — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the upcoming presentation of multiple oncology research abstracts at this year’s European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and...
Sep 7, 2022 9:15 AM ET
Illumina Genomics Forum To Feature Tennis Legend Chris Evert on the Role Genomics Played in Her Cancer Fight
SAN DIEGO, September 2, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1. Evert, who was diagnosed with stage 1C ovarian cancer earlier this year, will...
Sep 2, 2022 9:00 AM ET

Pages